Free Trial
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Maravai LifeSciences logo
$2.06 +0.04 (+1.72%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Key Stats

Today's Range
$2.02
$2.12
50-Day Range
$1.72
$3.25
52-Week Range
$1.67
$11.56
Volume
1.08 million shs
Average Volume
2.35 million shs
Market Capitalization
$525.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.34
Consensus Rating
Hold

Company Overview

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Maravai LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

MRVI MarketRank™: 

Maravai LifeSciences scored higher than 81% of companies evaluated by MarketBeat, and ranked 88th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Maravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Maravai LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Maravai LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Maravai LifeSciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Maravai LifeSciences is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Maravai LifeSciences has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Maravai LifeSciences' valuation and earnings.
  • Percentage of Shares Shorted

    5.56% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Maravai LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Maravai LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.56% of the float of Maravai LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Maravai LifeSciences has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Maravai LifeSciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Maravai LifeSciences has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Maravai LifeSciences this week, compared to 10 articles on an average week.
  • Search Interest

    Only 1 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.63% of the stock of Maravai LifeSciences is held by insiders.

  • Percentage Held by Institutions

    50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Maravai LifeSciences' insider trading history.
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

MRVI Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

MRVI Stock Analysis - Frequently Asked Questions

Maravai LifeSciences' stock was trading at $5.45 at the beginning of the year. Since then, MRVI stock has decreased by 61.2% and is now trading at $2.1150.
View the best growth stocks for 2025 here
.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.00 by $0.09. The company had revenue of $65.20 million for the quarter, compared to the consensus estimate of $67.58 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 6.61% and a negative net margin of 81.13%.
Read the conference call transcript
.

Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Top institutional shareholders of Maravai LifeSciences include SG Americas Securities LLC (0.27%), Bank of New York Mellon Corp (0.12%), Massachusetts Financial Services Co. MA (0.10%) and Rhumbline Advisers (0.06%). Insiders that own company stock include Gtcr Investment Xi Llc, Carl Hull and Kurt Oreshack.
View institutional ownership trends
.

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/07/2024
Today
5/02/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.34
High Stock Price Target
$13.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+202.7%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-119,030,000.00
Pretax Margin
159.33%

Debt

Sales & Book Value

Annual Sales
$259.19 million
Cash Flow
$0.05 per share
Price / Cash Flow
41.71
Book Value
$3.14 per share
Price / Book
0.67

Miscellaneous

Free Float
250,937,000
Market Cap
$533.09 million
Optionable
Optionable
Beta
0.18
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:MRVI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners